Agios Pharmaceuticals, Inc. (AGIO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AGIO SEC filings page.
Agios Pharmaceuticals, Inc. (AGIO) reported $98.3M in revenue over the twelve months to Jun 30, 2026, up 140.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Agios remains a development-stage business: revenue is rising, but R&D spending and cash outflows still overwhelm commercial receipts.
The FY2024 net profit was$674M while operating cash flow was-$390M , showing accounting earnings did not represent cash generated by operations. In FY2025, the company reported a net loss of$413M and operating cash flow of-$373M , bringing reported earnings and cash usage back into closer alignment.
Revenue rose to
Free cash flow was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Agios Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Agios Pharmaceuticals, Inc. held $1.2B in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $373.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Agios Pharmaceuticals, Inc. scores 62/100 among other emerging companies.
Agios Pharmaceuticals, Inc. had 59M shares outstanding at the end of fiscal year 2025, against 57M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Agios Pharmaceuticals, Inc. scores 64/100 among other emerging companies.
Agios Pharmaceuticals, Inc. spent $339.5M on research and development in fiscal year 2025, which was 64.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Agios Pharmaceuticals, Inc. scores 87/100 among other emerging companies.
Agios Pharmaceuticals, Inc. reported revenue of $54.0M in fiscal year 2025, against $36.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Agios Pharmaceuticals, Inc. scores 77/100 among other emerging companies.
Agios Pharmaceuticals, Inc.'s operations used $373.0M of cash in fiscal year 2025, against $389.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Agios Pharmaceuticals, Inc. scores 34/100 among other emerging companies.
Agios Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $1.2B at the end of fiscal year 2025, against $104.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Agios Pharmaceuticals, Inc. scores 96/100 among other emerging companies.
Agios Pharmaceuticals, Inc. scores 9.63, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.8B) relative to total liabilities ($104.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Agios Pharmaceuticals, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Agios Pharmaceuticals, Inc. reported a net loss of $413.0M while operations used $373.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Agios Pharmaceuticals, Inc. generated $44.7M in revenue in Q2 2026. This represents an increase of 259.3% from the same quarter a year earlier. Against the prior quarter it is up 115.7%.
Agios Pharmaceuticals, Inc. reported -$100.7M in net income in Q2 2026. This represents an increase of 10.1% from the same quarter a year earlier. Against the prior quarter it is down 1.6%.
Agios Pharmaceuticals, Inc. earned -$1.69 per diluted share (EPS) in Q2 2026. This represents an increase of 12.4% from the same quarter a year earlier. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Cash & Balance Sheet
Agios Pharmaceuticals, Inc. recorded an outflow of $58.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 25.0% from the same quarter a year earlier. Against the prior quarter it is up 51.1%.
Agios Pharmaceuticals, Inc. held $99.6M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Agios Pharmaceuticals, Inc.'s gross margin was 93.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 7.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.
Agios Pharmaceuticals, Inc.'s ROE was -9.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Agios Pharmaceuticals, Inc. invested $100.8M in research and development in Q2 2026. This represents an increase of 9.6% from the same quarter a year earlier. Against the prior quarter it is up 24.2%.
Agios Pharmaceuticals, Inc. invested $1.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 38.5% from the same quarter a year earlier. Against the prior quarter it is up 57.6%.
Not reported for Q2 2026.
AGIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.7M+259.3% | $20.7M+137.7% | $20.0M+86.1% | $12.9M+43.7% | $12.5M+44.6% | $8.7M+6.6% | $10.7M+51.1% | $9.0M+21.2% |
| Cost of Revenue | $3.0M+76.0% | $1.3M+21.6% | $1.9M+49.1% | $1.7M+114.4% | $1.7M+13.8% | $1.1M+73.0% | $1.3M+115.0% | $783K+23.7% |
| Gross Profit | $41.7M+288.3% | $19.4M+154.2% | $18.1M+91.0% | $11.2M+36.9% | $10.8M+51.0% | $7.6M+1.0% | $9.5M+45.3% | $8.2M+20.9% |
| R&D Expenses | $100.8M+9.6% | $81.1M+11.6% | $88.1M+6.3% | $86.8M+19.8% | $91.9M+18.8% | $72.7M+6.0% | $82.8M+6.9% | $72.5M-11.5% |
| SG&A Expenses | $51.5M+12.4% | $48.3M+16.3% | $51.6M-0.2% | $41.3M+7.1% | $45.9M+29.1% | $41.5M+33.9% | $51.7M+46.4% | $38.5M+49.2% |
| Operating Income | -$110.6M+13.0% | -$110.0M-3.2% | -$121.6M+2.8% | -$116.9M-13.7% | -$127.1M-20.1% | -$106.6M-15.8% | -$125.0M-17.7% | -$102.8M-1.9% |
| Income Tax | N/A | N/A | N/A | $0-100.0% | N/A | N/A | N/A | $53.1M |
| Net Income | -$100.7M+10.1% | -$99.1M-11.0% | -$108.3M-12.5% | -$103.4M-110.9% | -$112.0M-16.5% | -$89.3M-9.5% | -$96.2M-0.4% | $947.9M+1138.0% |
| EPS (Basic) | -$1.69+12.4% | -$1.69-9.0% | -$1.85-7.6% | -$1.78-110.7% | -$1.93-14.2% | -$1.55-6.9% | -$1.720.0% | $16.65+1115.2% |
| EPS (Diluted) | -$1.69+12.4% | -$1.69-9.0% | -$1.85-6.3% | -$1.78-111.0% | -$1.93-14.2% | -$1.55-6.9% | -$1.74-1.2% | $16.22+1089.0% |
| Diluted Shares (Avg) | 59M+2.7% | 59M+2.3% | N/A | 58M-0.5% | 58M+2.0% | 57M+1.9% | N/A | 58M+4.7% |
Not reported in any period shown, so not listed: EBITDA, Interest Expense.
AGIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B-24.7% | $1.2B-23.8% | $1.3B-22.0% | $1.4B-22.7% | $1.5B+90.3% | $1.6B+83.1% | $1.7B+77.5% | $1.8B+77.9% |
| Current Assets | $717.7M-29.6% | $834.8M-13.8% | $942.1M-2.4% | $1.0B-3.8% | $1.0B+61.3% | $968.6M+46.0% | $965.6M+15.8% | $1.1B+52.5% |
| Cash & Equivalents | $99.6M+23.2% | $113.6M+43.9% | $89.1M+16.9% | $92.7M-63.5% | $80.9M-4.3% | $79.0M-33.5% | $76.2M-13.6% | $253.7M+294.4% |
| Short-Term Investments | $517.9M-39.6% | $623.4M-23.4% | $765.3M-6.4% | $860.1M+14.5% | $858.1M+76.8% | $814.4M+69.9% | $817.5M+18.7% | $751.0M+28.8% |
| Inventory | $35.8M+15.9% | $35.1M+18.5% | $32.9M+19.2% | $32.0M+21.2% | $30.8M+28.9% | $29.6M+28.3% | $27.6M+44.8% | $26.4M+53.0% |
| Long-Term Investments | $347.3M-13.3% | $308.5M-41.9% | $310.0M-51.4% | $304.3M-53.6% | $400.5M+431.1% | $531.3M+356.8% | $638.3M+2068.6% | $655.9M+191.6% |
| Total Liabilities | $82.4M-19.0% | $75.9M-14.7% | $104.1M-14.8% | $101.4M-38.6% | $101.7M-9.7% | $89.0M-15.9% | $122.2M-3.1% | $165.1M+37.1% |
| Current Liabilities | $70.2M-0.3% | $58.8M+12.4% | $82.2M+1.3% | $74.8M-37.4% | $70.4M+12.4% | $52.4M+1.3% | $81.2M+19.4% | $119.5M+104.5% |
| Non-Current Liabilities | $12.2M-61.0% | $17.0M-53.5% | $21.9M-46.7% | $26.6M-41.7% | $31.3M-37.4% | $36.6M-32.3% | $41.1M-29.3% | $45.7M-26.3% |
| Total Equity | $1.0B-25.1% | $1.1B-24.4% | $1.2B-22.6% | $1.3B-21.0% | $1.4B+107.3% | $1.5B+97.1% | $1.5B+90.0% | $1.6B+83.4% |
| Retained Earnings | -$761.5M-117.4% | -$660.8M-177.4% | -$561.7M-277.2% | -$453.7M-765.8% | -$350.2M+65.0% | -$238.2M+73.7% | -$148.9M+81.9% | -$52.4M+92.8% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
AGIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$57.3M+25.7% | -$118.9M-6.7% | -$96.2M+27.8% | -$88.2M-4.7% | -$77.1M-6.2% | -$111.5M-11.6% | -$133.2M-83.7% | -$84.2M-36.6% |
| Stock-Based Compensation | $15.9M+8.5% | $15.5M+36.8% | N/A | $12.4M+11.1% | $14.7M+27.0% | $11.4M+23.0% | N/A | $11.1M+22.8% |
| Capital Expenditures | $1.2M+38.5% | $769K+0.4% | $1.1M+15.8% | $1.6M+271.1% | $875K+453.8% | $766K+443.3% | $967K+313.2% | $419K+13.6% |
| Free Cash Flow | -$58.5M+25.0% | -$119.7M-6.6% | -$97.3M+27.4% | -$89.7M-6.0% | -$78.0M-7.2% | -$112.3M-12.2% | -$134.1M-84.4% | -$84.6M-36.5% |
| Investing Cash Flow | $40.2M-49.1% | $141.3M+25.5% | $90.1M+283.2% | $95.6M-61.9% | $79.0M+112.0% | $112.6M-9.6% | -$49.2M-151.5% | $250.8M+537.5% |
| Financing Cash Flow | $3.1M+4744.6% | $2.1M+28.4% | $2.6M-47.2% | $4.4M+68.2% | $65K-94.1% | $1.6M-72.4% | $4.8M+471.7% | $2.6M+40.1% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid, Share Buybacks.
AGIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.3%+7.0pp | 93.6%+6.1pp | 90.6%+2.3pp | 87.0%-4.3pp | 86.3%+3.7pp | 87.6%-4.8pp | 88.3%-3.5pp | 91.3%-0.2pp |
| Operating Margin | -247.1% | -530.3% | -608.9% | -907.4% | -1020.1% | -1222.0% | -1165.3% | -1146.9% |
| Net Margin | -225.1% | -477.7% | -542.2% | -803.0% | -899.4% | -1023.3% | -897.0% | 10574.7% |
| Return on Equity | -9.8%-1.6pp | -8.9%-2.8pp | -9.1%-2.8pp | -8.1%-66.3pp | -8.2%+6.4pp | -6.1%+4.9pp | -6.2%+5.6pp | 58.3%+68.6pp |
| Return on Assets | -9.1%-1.5pp | -8.4%-2.6pp | -8.3%-2.6pp | -7.5%-60.4pp | -7.6%+4.8pp | -5.7%+3.9pp | -5.8%+4.4pp | 52.9%+62.0pp |
| Current Ratio | 10.22-4.3x | 14.19-4.3x | 11.46-0.4x | 13.82+4.8x | 14.48+4.4x | 18.50+5.7x | 11.90-0.4x | 8.99-3.1x |
| Debt-to-Equity | 0.080.0x | 0.070.0x | 0.090.0x | 0.080.0x | 0.07-0.1x | 0.06-0.1x | 0.08-0.1x | 0.100.0x |
| Asset Turnover | 0.040.0x | 0.020.0x | 0.020.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.010.0x |
| FCF Margin | -130.8% | -576.9% | -487.5% | -696.5% | -626.3% | -1286.4% | -1250.1% | -944.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. AGIO | FY2025 | $54.0M | -$413.0M | N/A | $1.8B | 70/100 |
| Travere Therapeutics, Inc. TVTX | FY2025 | $490.7M | -$25.5M | -5.2% | $4.9B | 71/100 |
| Denali Therapeutics Inc. DNLI | FY2025 | $0 | -$512.5M | N/A | $3.1B | — |
| Disc Medicine, Inc. IRON | FY2025 | N/A | -$212.2M | N/A | $2.4B | — |
| Amicus Therapeutics, Inc FOLD | FY2025 | $634.2M | -$27.1M | -4.3% | $4.5B | 44/100 |
| Apogee Therapeutics, Inc. APGE | FY2025 | N/A | -$255.8M | N/A | $10.2B | — |
Where Agios Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Agios Pharmaceuticals, Inc.'s annual revenue?
Agios Pharmaceuticals, Inc. (AGIO) reported $54.0M in total revenue for fiscal year 2025. This represents a 48.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Agios Pharmaceuticals, Inc.'s revenue growing?
Agios Pharmaceuticals, Inc. (AGIO) revenue grew by 48.0% year-over-year, from $36.5M to $54.0M in fiscal year 2025.
Is Agios Pharmaceuticals, Inc. profitable?
No, Agios Pharmaceuticals, Inc. (AGIO) reported a net income of -$413.0M in fiscal year 2025.
What is Agios Pharmaceuticals, Inc.'s EBITDA?
Agios Pharmaceuticals, Inc. (AGIO) had EBITDA of -$466.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Agios Pharmaceuticals, Inc.'s gross margin?
Agios Pharmaceuticals, Inc. (AGIO) had a gross margin of 88.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Agios Pharmaceuticals, Inc.'s return on equity (ROE)?
Agios Pharmaceuticals, Inc. (AGIO) has a return on equity of -34.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Agios Pharmaceuticals, Inc.'s free cash flow?
Agios Pharmaceuticals, Inc. (AGIO) recorded an outflow of $377.3M in free cash flow during fiscal year 2025. This represents a 3.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Agios Pharmaceuticals, Inc.'s operating cash flow?
Agios Pharmaceuticals, Inc. (AGIO) recorded an outflow of $373.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Agios Pharmaceuticals, Inc.'s total assets?
Agios Pharmaceuticals, Inc. (AGIO) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Agios Pharmaceuticals, Inc.'s capital expenditures?
Agios Pharmaceuticals, Inc. (AGIO) invested $4.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Agios Pharmaceuticals, Inc. spend on research and development?
Agios Pharmaceuticals, Inc. (AGIO) invested $339.5M in research and development during fiscal year 2025.
What is Agios Pharmaceuticals, Inc.'s current ratio?
Agios Pharmaceuticals, Inc. (AGIO) had a current ratio of 11.46 as of fiscal year 2025, which is generally considered healthy.
What is Agios Pharmaceuticals, Inc.'s debt-to-equity ratio?
Agios Pharmaceuticals, Inc. (AGIO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Agios Pharmaceuticals, Inc.'s return on assets (ROA)?
Agios Pharmaceuticals, Inc. (AGIO) had a return on assets of -31.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Agios Pharmaceuticals, Inc.'s P/E ratio?
Agios Pharmaceuticals, Inc. (AGIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.8B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Agios Pharmaceuticals, Inc.'s price-to-sales ratio?
Agios Pharmaceuticals, Inc. (AGIO) trades at 18.7x sales, its market capitalization divided by revenue of $98.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.8B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Agios Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Agios Pharmaceuticals, Inc. (AGIO) held $1.2B in cash, cash equivalents and investments, and reported an operating cash outflow of $373.0M over that year. Dividing the one by the other, the reported balance equals about 37 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Agios Pharmaceuticals, Inc.'s Altman Z-Score?
Agios Pharmaceuticals, Inc. (AGIO) has an Altman Z-Score of 9.63, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Agios Pharmaceuticals, Inc.'s Piotroski F-Score?
Agios Pharmaceuticals, Inc. (AGIO) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Agios Pharmaceuticals, Inc.'s earnings high quality?
Agios Pharmaceuticals, Inc. (AGIO) reported a net loss of $413.0M while operations used $373.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Agios Pharmaceuticals, Inc.?
Agios Pharmaceuticals, Inc. (AGIO) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.